EGFR and colorectal carcinoma: It was also demonstrated that the suppression of EGFR by cetuximab, erlotinib, gefitinib, and vemurafanib causes an inhibiting effect on CRC with the BRAF mutation in both ‘in vitro’ and ‘in vivo’ models, results of which indicate that combination therapy with BRAF and EGFR inhibitors may be more effective.